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ApoptosisDespite the tremendous amount of data over the last 40 years, lack of gap junctional intercellular communi-
cation (GJIC) or altered expression of gap junction proteins is still a lesser known ‘hallmark’ of cancer. Expres-
sion of astrocytic gap junction protein, connexin43 (Cx43), is often reduced in astrocytomas, the most
common neoplasia of the central nervous system (CNS) in adults. Supported by a number of evidences, the
global decrease of Cx43 expression appears to be advantageous for the growth of glioma cells. Although
the mechanisms by which Cx43 regulates the expression levels of proteins involved in cell growth is unclear,
there are evidences to suggest that it might be independent of their channel forming properties. In this re-
gard, the carboxyl tail of Cx43 may have the ability to control the translocation of transcription factor regu-
lators into the nucleus. However, this putative tumor suppressor effect of Cx43 is counterbalanced by its
capacity to enhance the migration of glioma cells out of the tumor core through mechanisms that seems to
implicate its carboxyl tail, possibly by interacting with the actin cytoskeleton. This ambivalence between
the tumor suppressor effect and promotion of cell migration may partly be explained by the heterogeneous
expression of Cx43 in the glioma core especially at the malignant glioblastoma stage; some tumor cells would
be expected to migrate (Cx43 expressing cells) and others to proliferate (non-expressing Cx43 cells). More-
over, the involvement of Cx43 in glioma progression seems to be more complex since, in addition, GJIC may
increase their resistance to apoptosis and Cx43 may also affect cell homeostasis in a paracrine fashion via
hemichannel action. In conclusion, Cx43 appears to be involved at different levels of the glioma progression
by acting on cell growth regulation, promotion of cell migration and resistance to apoptosis. This article is
part of a Special Issue entitled: The Communicating junctions, composition, structure and characteristics.
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Tumors of the central nervous system (CNS) are relatively rare
compared to other tumor types, accounting for less than 2% of all ma-
lignancies [1]. However, brain cancer is often lethal and the average
survival rate of patients is about 1 year after diagnosis. Current treat-
ment consisting of surgery, radiation and chemotherapy has not been
very effective due to the heterogeneity of the tumor and the seamless
integration of tumor mass with the normal brain parenchyma. Astro-
cytomas are the most prominent form of glioma in adults and have
been traditionally classiﬁed by the World Health Organization
(WHO) into 4 grades, of which grade IV is the most malignant.
Grade III (anaplastic astrocytomas) shows increased cellularity and
atypical nuclei while grade IV glioblastoma multiform (GBM) consists
of microvascular proliferation and pseudopalisading necrosis [2].
However, tumor grading based only on morphological criteria has
its limitations as it becomes clear that gliomas with different pathol-
ogies may share similar gene mutations. In this aspect, DNA copy
number alterations and gene expression proﬁling carried out on
grade III/IV astrocytomas have revealed several core pathways that
are commonly altered and consequently, The Cancer Genome Atlas
research network (TCGA) put forward a gene-based subdivision of
grade III/IV astrocytomas into proneural, neural, proliferative/classi-
cal and mesenchymal subtypes [3–5].
2. Aberrant expression of Cx43 in primary human gliomas
Historically, gliomas were thought to arise from malignantly
transformed astrocytes as they histologically resemble glial cells but
recent evidence also suggests the role of cancer stem cells (CSCs) in
driving glioma pathologenesis [6–10]. While the origin of these CSCs
is still a subject of intense debate [11], there have been suggestions
that neural stem cells (NSCs) and/or progenitors contribute to brainTable 1
Previous studies on connexin expression in human astrocytomas.
References Samples Techniques Conclusions
[24] 18 tumor samples IHC Decreased expression of Cx43 in
high grade tumors
Grade II: 4
Grade III: 8
Grade IV: 6
[28] 24 tumor samples IHC, WB Increased expression of Cx43 in gliosis
areas in grade II tumors. Decreased
expression of Cx43 or delocalization in
the cytoplasm in high grade tumors (in
the context of glioma-induced epilepsy)
Grade II: 8
Grade III: 8
Grade IV: 8
[26] 8 tumor samples IHC Decreased expression of Cx43 in high
grade tumors linked with a decreased
gap junction coupling (in vitro)
Grade II: 2
Grade IV: 6
[25] 44 tumor samples NB, IHC,
WB
Decreasing RNA amount and Cx43
expression with gradeGrade I: 4
Grade II: 12
Grade III: 14
Grade IV: 14
[27] 32 tumor samples ISH, IHC Persistence of RNA for Cx43 in high
grade tumors but decreased expression
of Cx43 protein
Grade I: 7
Grade II: 5
Grade III: 7
Grade IV: 13
IHC: Immunohistochemistry. ISH: In SituHybridization. NB: Northern blot.WB:Western blot.
NOTE: Unless speciﬁed in the study, only astrocytomas are mentioned.tumor heterogeneity [12–14]. In addition, there are also obvious sim-
ilarities in the molecular biology of migration between glioma and
neural progenitor cells [15].
Gap junction mediated communication has been detected in both
astrocytes and neural progenitors [16,17]. While Cx43 and Cx30 are
highly expressed in astrocytes [18,19], Cx43 and Cx26 are the pre-
dominant connexin proteins in neural progenitors [20–22]. As Cx43
are expressed in both astrocytes and neural progenitors [23] that
are believed to be the origin of gliomas, this review will focus on its
functional role in glioma growth and migration.
Mis-expression of Cx43 in primary human gliomas has been inves-
tigated in a few studies with a limited number of samples (Table 1). In
general, decreasing Cx43 expression is associatedwith increasing pro-
liferation and higher tumor grades. A screen of 18 primary tumor sam-
ples revealed low expression of Cx43 protein in grade III and IV tumors
[24]. In a larger screen of 44 tumors, decreasing Cx43 protein and
mRNA expression was correlated with increasing Ki67 proliferative
index in high-grade gliomas [25]. A similar result was also obtained
by another group [26]. However, a recent study with 32 human sam-
ples reported high levels of Cx43 mRNA but low levels of Cx43 protein
in high-grade gliomas [27], suggesting a post-transcriptional regula-
tion of Cx43 protein. Indeed, it appears that the phosphorylation
state and localization of Cx43 vary with tumor grades [28]. While
low-grade gliomas show increased levels of Cx43 protein that are lo-
calized to the membrane and therefore presumably functional, Cx43,
if present in high-grade tumors, is often non-phosphorylated and ex-
hibits a predominantly cytoplasmic localization [28].
Recently, the availability of large-scale genomic and expression
datasets has allowed the investigation of any gene of interest on hun-
dreds of primary human tumor samples. TCGA (http://tcga-data.nci.
nih.gov/tcga/), the Rembrandt repository for molecular brain neopla-
sia data (https://caintegrator.nci.nih.gov/rembrandt/), and Oncomine
(https://www.oncomine.org/) are three of the databases that are par-
ticularly relevant to obtain clinical evidence that suggests aberrant
expression of Cx43 contributes to human gliomagenesis.
A query on TCGA repository revealed that Cx43 gene was deleted in
11.3% (42/372) of primary grade III/IV astrocytomas. For comparison,
23.7% (88/372) of GBM samples showed a reduction of retinoblastoma
(RB1), a well established tumor suppressor identiﬁed as a core player
in gliomagenesis. Therefore, the genomic data seems to suggest that
the loss of Cx43 facilitates tumor formation and that Cx43 acts as a
growth suppressor. However, the mRNA expression proﬁle of Cx43 in
GBM is less clear cut. Although 57% of primary tumors with more than
2-fold changes show a reduction of Cx43 level, the rest shows an in-
creased Cx43 expression (source: TCGA repository). A similar result
was also obtained with Oncomine expression analysis. On the other
hand, gene expression query with Rembrandt repository revealed no
difference in Cx43 expression over a whole range of brain tumor sub-
types. Taken together, it is clear that Cx43 expression is highly hetero-
geneous, and its level of expression may be dependent on the local
tumor microenvironment, such as the presence of Cx43-expressing
non-transformed astrocytes (Sin et al., unpublished data). Therefore, it
is conceivable that Cx43 may perform different functions depending
on the cellular status of the tumor.
3. Mechanisms of Cx43 in gliomagenesis
A tumor cell exhibits characteristics of what are commonly known
as hallmark of cancers [29,30] which includes the increase of
Table 2
Connexins and the regulation of cellular proliferation.
Models Regulated proteins Effects on cell cycle/proliferation References
Regulation of proteins involved in cell cycle by Cx43
Cx43-transfected dog kidney epithelial TRMP cell line Cyclin A1 ↓ Increased duration of G1-S transition phase [41]
Cyclin D1 ↓
Cyclin D2 ↓
Cdk6 ↓
Cdk5 ↓
Cx43-transfected osteosarcoma U2OS cell line Skp2 ↓ p27 ↑ [37,42]
Block of G1-S transition phase
GJ-blockers-treated astrocytes Cyclin D1↑ Rb phosphorylation (Ser280) ↑ [45]
Cyclin D3↑ Proliferation ↑
Regulation of growth suppressors by Cx43
Cx43-expressing C6 glioma cell line Osteopontin ↑ Proliferation ↓ [49]
Cx43-expressing C6 glioma cell line CCN3 ↑ Proliferation ↓ [50]
Cx43-expressing C6 glioma cell line MPG-E8 ↓ Induction of contact growth inhibition [48]
Cx43-expressing C6 glioma cell line IGFPB3 ↓ Proliferation ↓ [46,47]
IGFBP4 ↑
IGF-1 ↓
Cx43-transfected U251 glioma cell line MCP-1 ↓ Proliferation ↓ [51]
Regulation of proteins involved in cellular proliferation
Cx43-transfected cardiomyocytes β-catenin Decreased transactivation potential of β-catenin correlated with
colocalization of Cx43 and β-catenin
[84]
Cx43-expressing C6 glioma cells c-Src Tyr244 and Tyr265 are phosphorylated by c-Src. As long as these
Tyr residues are present, Cx43 acts as a substrate for c-Src and
prevents its proliferation effects
[44]
p21 ↑, p27 ↑
Rb phosphorylation ↓, Cyclin E ↓
Block of G1-S transition phase
Regulation of Connexins/GJIC
TGF-β1-treated astrocytes Cx43 phosphorylation ↑ DNA synthesis ↓ [64]
GJIC ↑
TGF-β1-treated C6 glioma cells Cx43 phosphorylation ↓ DNA synthesis ↑ [64]
GJIC ↓
Tolbutamide-treated C6 glioma cells GJIC ↑ p21 ↑, p27 ↑, Rb phosphorylation ↓ [43,65]
Cell growth ↓
CNTFR-alpha treated C6 glioma cells GJIC ↑ Cell growth ↓ [66]
FGF-2-treated cardiomyocytes Phosphorylation of Cx43 ↑ by εPKC on
S262 correlated with GJIC↓
FGF-2 is a potent mitogenic factor highly expressed in gliomas [70–73]
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to apoptosis. In this aspect, the role of Cx43 in affecting growth con-
trol and regulating cellmigration, such as in development (embryogen-
esis) [31], tissue maintenance (wound healing) [32] and pathology
(cancer progression) [33] has been well studied. Consequently, the reg-
ulation of Cx43 signaling, such as by phosphorylation with kinases [34]
and its interaction with other proteins [35] extensively studied in pe-
ripheral tissues will be useful in deciphering themolecularmechanisms
in glioma progression.3.1. Effect on cell growth
All studies so far have reported Cx43 as a negative regulator of
glioma cell growth regardless of species origin (human or rodents)
or tumor cell types [33,36]. It appears that Cx43 affects the cell
cycle by preventing the transition to the S-phase [37–39] or to the
M-phase [40]. Cx43 expression seems to induce similar effects what-
ever the origin of the transformed/cancer cell lines used (kidney epi-
thelium, osteosarcoma, lung carcinoma, glioma) [37,41–43]. Globally,
the transition from G1 to S phases is longer (G1 delay); an effect that
is related to expected changes of expression levels of genes involved
in cell cycle regulation. This implies a decrease in the expression of
proteins involved in the progression of the cell cycle that include
cyclins A, D1, D2, E, cdk5, cdk6, skp2; or an increase in the protein
levels of those that prevent it, such as p21 and p27 [37,41–45].
In addition to changes in cell cycle regulatory proteins, Cx43 may
also affect the expression of other growth suppressors (Table 2). Forinstance, Cx43 transfection of C6 rat glioma cells also modiﬁes the ex-
pression of secreted proteins, which either resulted in increasing
(osteopontin, CCN3, IGFBP4) or decreasing (MPG-E8, IGF-1, IGFBP3)
protein levels [46–50]. Similarly, a diffusible factor such as MCP-1
was found to be downregulated in human glioblastoma cells trans-
fected by Cx43 [51], which opens up the possibility of which changes
in the expression pattern of secreted proteins may modulate growth
via paracrine effect [52,53]. The extended modiﬁcation of gene ex-
pression (not only about cell cycle proteins) ﬁts well with the obser-
vation that the expression of more than 250 genes is altered in
astrocytes from Cx43-deﬁcient mice [54–56].
It is still unclear how Cx43 regulates gene expression. Before dis-
cussing this aspect, we have to consider that gap junction isoforms are
not functionally equivalent. Unlike Cx43, overexpression of Cx32 has
no effect on C6 cell growth [57]. Generally, the inhibition of cell growth
seems to be connexin isoform-speciﬁc [58]. This speciﬁcity is mostly at-
tributed to two properties: the channel permeability and their unique
intracellular region. Both of them can be related since the intracellular
domain (especially the carboxyl tail) may regulate the channel perme-
ability by conformational changes via phosphorylation [59]. For this re-
view, we will consider these functionalities separately.3.1.1. Regulation of cell growth by channel-dependent mechanisms
Cx43 exhibits enhanced permeability to some metabolites includ-
ing ATP and glutamate when compared to Cx32 [60,61]. Such a differ-
ential permeability may favor speciﬁc transmission of growth
inhibitory factors that is yet to be identiﬁed through gap junction
A - Channel-dependent functions
GJIC allows propagation of growth inhibitory factors
Cytosol
Tolbutamide
CNTF
dbcAMP
FGF-2
P-Tyr244
Exogenous 
Cx43
S
G2
M
P-Ser262
P-Tyr265
Growth inhibitory 
factors
B - Channel-independent functions
Sequestration of putative gene regulators Cx as a putative regulator of gene expression
S
Cytosol
           
P
P
ExtracellularExtracellular
PTF PTF
NucleusNucleus
PTFPTF
Cytosol
Cell growth 
activator genes
Cell growth 
inhibitor genes
PTF
G1
or
Cytosol
Fig. 1. Connexin43 and cell growth regulation. Connexin43 (Cx43) may exert a regulation on cell growth via channel-dependent functions (A) as well as by channel-independent
functions (B). A: Drugs or molecules such as tolbutamide, ciliary neurotrophic factor (CNTF) or dibutyryl-cyclic adenosine monophosphate (dbc-AMP) are known to increase gap
junctional intercellular communication (GJIC) and concomitantly reduce the cell cycle progression in C6 glioma cells [43,65,66]. Moreover, the phosphorylation by c-Src of Tyrosine
244 and 265 (Tyr244 and Tyr265 respectively) has been proposed as a way to maintain c-Src at the membrane level avoiding it to exert its positive effects on cell cycle [44]. On the
contrary, the phosphorylation of Serine 262 (Ser262) following a FGF-2 treatment leads to a decreased GJIC that is linked with DNA synthesis [72]. The expression of exogenous
Cx43 has been associated with the restoration of GJIC. Putative growth inhibitory signals that remain to determine may then pass through the channels as GJIC is correlated
with a decreased cell proliferation or an increased G1-S transition phase [37,41,42]. B: Cx43 may also regulate the expression of genes via channel-independent functions. Thus,
Cx43 may interact with proteins involved in signaling pathways or putative transcription factors (PTF) such as β-catenin, Src, CCN3 or Zonula Occludens-1. These interactions
may prevent their translocation into the nucleus avoiding the induction of target genes involved in cell growth [71,82–85]. The translocation of Cx43 or at least a part of the protein
in the nucleus has also been proposed. Alone or in interaction with other proteins (β-catenin, Src), Cx43 might induce the transcription of cell growth inhibitor genes [41,78,86,88].
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an alternate route by which Cx43 may affect cancer cell metabolism.
A few studies have demonstrated the correlation of cell growth
with intercellular communication by growth factors or drugs (see
Table 2). For instance, inhibition of GJIC by TGF-β1 is correlated to
the appearance of a phosphorylated form of Cx43 in C6 rat glioma
cells, leading to increased DNA synthesis. Interestingly, this effect
was reversed in non-transformed astrocytes [64]. It appears that
DNA synthesis is affected by the extent of GJIC in C6 cells. According-
ly, the increase of GJIC by tolbutamide leads to reduced growth of C6
cells [43,65]. Similar effect was observed for CNTF when used with its
soluble receptor (CNTFR-alpha) in C6 cells that resulted in increased
GJIC due to upregulated Cx43 expression, leading to reduced cell
growth [66] (Fig. 1A; Table 2).
Phosphorylation of Cx43 especially at its carboxyl tail has been
shown to affect GJIC by affecting the trafﬁcking, assembly and degra-
dation of the protein [34,67]. Since many kinases are implicated to in-
teract with Cx43, it is necessary to mention the possible role of Cx43
phosphorylation in cell growth control. Phosphorylation of Cx43 af-
fects its structure [68], leading to changes in its gating properties
[69] and interacting partners [35]. In addition, internalization and
degradation of Cx43 are also linked to its phosphorylation state
[59]. A particularly well studied example is S262 amino acid of Cx43
which is phosphorylated by εPKC in response to FGF-2 stimulation,
inducing DNA synthesis with a concurrent reduction of GJIC [70,71].
Although this study is carried out in cardiomyocytes, the cellular ef-
fects due to phosphorylation of S262 [72] could be applicable to the
regulation of Cx43 in glioma cells since FGF-2 is known to be highlyexpressed in gliomas (in a grade dependent manner) and is a potent
autocrine/paracrine mitogenic factor of glioblastoma cells [73,74]
(see Fig. 1A and Table 2).
3.1.2. Regulation of cell growth by channel-independent mechanisms
As mentioned earlier, increased expression of connexin genes in
tumor cells enhances GJIC and inhibits cell growth; and this effect ap-
pears to be connexin-species speciﬁc but does not always correlate
with the level of GJIC [58]. In several cases and independently of the
cell types, it has been reported that Cx43 can inhibit cell growth in
a manner independent of channel permeability [75–77]. The growth
of human glioblastoma cells was reduced by expression and localiza-
tion of Cx43 in the cytoplasm without a corresponding increase in
coupling [78]. It is not knownwhy Cx43 was kept as an unphosphory-
lated form and was not targeted to the plasma membrane in those
cells. Apparently, the cytoplasmic localization of Cx43 is sufﬁcient
for downregulating cell growth since it has been observed in other
cell types by using mutated Cx43 [75,79]. Since Cx43 has been fre-
quently observed in the cytoplasm of tumor cells in gliomas [28], it
would be interesting to understand if cytoplasmic Cx43 has an alter-
native role in cell growth control.
The carboxyl tail of Cx43 is a considerable part of the molecule (2/3
of the total length of Cx43) and is a domainwithmultiple potential sites
for interacting proteins [35]. Therefore, growth regulation might be
controlled by interacting proteins such as CCN3 which is upregulated
in Cx43-transfected cells and colocalizes with gap junction plaques
[50,80,81]. CCN3 speciﬁcally interacts with Cx43 through its carboxyl
tail domain (from 244 to 382 amino acid) and it is proposed that the
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where it would stimulate cell growth [50,81] (Fig. 1B). It is interesting
to speculate that Cx43 may modulate speciﬁc signaling pathways by
sequestering intracellular messengers in the cytosol close to the plasma
membrane in order to prevent them from translocating into the nucleus
and changing the gene expression pattern towards an increased cell
growth. Cx43 would then act in a similar fashion as cadherins in pre-
ventingβ-catenin to translocate into the nucleus to activate thewnt sig-
naling pathway [82,83]. Interestingly, it was shown that Cx43may have
similar regulatory mechanisms as cadherins by controlling its own ex-
pression via the nuclear translocation of β-catenin in cardiomyocytes
[84]. Other Cx43 interacting proteins that can regulate the cell cycle
may include proteins such as ZO-1, εPKC and Src, which have been im-
plicated in regulation of cell proliferation [70,84,85]. A recent report
demonstrated an alternative mechanism that Cx43 can reduce cell
growth by acting as a substrate for c-Src and thereby reduces Src in-
volvement in cell growth activation [44].
More intriguing is cell growth control associated with the nuclear
localization of Cx43 in various cell types either after transfection of
Cx43 cDNA [41,78,86]. Similar observations were made in situ in
colon cancer (personal communication) or in gliomas in situ (Crespin
et al. unpublished data). Since it is hard to believe that an integral
membrane protein like Cx43 may enter into the nucleus, it is sug-
gested that its carboxy-terminal domain may possess the nuclear
targeting function [87]. Interestingly, it appears that the non-
channel forming carboxy-terminal ‘tail’ of Cx43 retains growth inhib-
itory activity [77,88] by localizing to the nucleus [88]. From such
observations, it has been speculated that Cx43 may affect gene ex-
pression directly, acting as a transcription factor (even if, to our
knowledge, no DNA-binding motif has been clearly demonstrated in-
side the Cx43 protein sequence), or indirectly by interacting with
transcription affecting protein(s) or complexes (Fig. 1B). This ability
of the Cx43 carboxyl tail to enter the nucleus is not cell-type speciﬁc
and can occur independently of whether cells express or not endoge-
nous Cx43 in cardiomyocytes and HeLa cells [88]. Interestingly,
the apparent size of the carboxy-terminal fragment was higher
(20 kDa) than expected (15 kDa) suggesting the presence of post-
translational modiﬁcations [88]. Since no conventional nuclear local-
ization sequence (NLS) is present in the Cx43 carboxyl tail, one can
speculate that it may enter the nucleus by interacting, directly or
not, with other proteins possessing NLS signals that are known to in-
teract with the Cx43 carboxyl tail and translocate to the nucleus such
as src, εPKC and β-catenin.
3.2. Effect on cell migration
Cx43 appears to be a pivotal protein that regulates expression of
genes not only related to cell-cycle control (as discussed in previous
section) but also genes with wider roles such as reversing epithelial–
mesenchymal transition (EMT). For instance, overexpression of Cx43
in C6 glioma cells shifts their morphology from a mesenchymal to
an epithelial phenotype [89], and this has also been observed in breast
cancer cells [90]. In addition, Cx43 also appears to regulate cell polar-
ity in neural crest cells and epicardial EMT [91,92]. Interestingly, a
study carried out with primary human GBM derived progenitors
revealed arrested neuronal differentiation and advanced mesenchy-
mal differentiation compared to normal neural progenitors [93]. As
Cx43 is required for proper neurogenesis by radial glial progenitors
[94], we speculate that Cx43 (or lack of) may even have a role in glio-
ma initiation.
Data associating connexins and cell migration were mostly accu-
mulated during the last decade. Such an association ﬁrst came from
the observation that the migration of neural crest cells depends on
their level of Cx43 expression [95,96]. In vitro, it was shown that
these cells exhibit a low motility when Cx43 is knocked out [95,96]
while its overexpression enhances cell motility [91]. This correlationbetween Cx43 expression and cell motility appears to be a more gen-
eral phenomenon, which is observed in a large variety of cell types in-
cluding mouse embryonic endothelial progenitors, HeLa cells and
NIH-3T3 cells [97,98]. In addition, elucidating the mechanisms involv-
ing gap junctions in glioma invasion can be gleaned from studies on
Cx43 in early brain development [94,99–102]. For gliomas, there ap-
pears to be a positive correlation of Cx43 with migration [89,103,104].
3.2.1. Regulation of cell migration by channel-dependent mechanisms
If Cx43 expression is correlated to glioma cell migration and seems
to govern it, the mechanisms which are involved are still unclear. As a
gap-junction protein, Cx43 could be expected to control cell migra-
tion through the establishment of GJIC. However, the involvement
of a channel activity in such a process is controversial and depends
whether GJIC is established between glioma cells (homocellular
GJIC) or between glioma cells and astrocytes which are the major
cell type of the brain stroma (heterocellular GJIC). For instance, the
inhibition of homocellular GJIC between GL15 human glioblastoma
cells by carbenoxolone increased cell motility while similar inhibition
of heterocellular GJIC in the presence of astrocytes decreased GL15
motility [105]. Certainly, direct GJIC has been demonstrated between
glioma cells and astrocytes in vivo and in vitro [89,106,107]. In addi-
tion, this interaction is capable of modifying the morphology and
gene expression of astrocytes [106,107]. GJIC between glioma cells
and endothelial cells [108] is also predicted to have a critical role in
glioma invasion. Accordingly, the upregulation of Cx43 in breast can-
cer micrometastases appears to facilitate their attachment to pulmo-
nary endothelium [109]. Taken together, migration of glioma cells is
optimal when GJIC is low between them but high with the stromal
cells. A recent publication clearly illustrates the lack of Cx43 increases
the motility of U251 glioma cells in a wound healing assay, but down-
regulation of Cx43 hindered the invasion of these cells in a brain slice
[110]. Interestingly, this observation is consistent with low Cx43 ex-
pression within the core of the glioblastoma (Table 1) and high
Cx43 expression in the peri-tumor astrocytic stroma [28,111].
3.2.2. Regulation of cell migration by channel-independent mechanisms
However, some in vitro studies reported the lack of effect of GJIC
inhibition on C6 glioma motility [104]. And there is an increasing
amount of data showing that glioma motility may be controlled by
gap junction channel-independent mechanisms. For instance, the
increased cell adhesion due to extracellular loop of Cx43 [112] may
facilitate migration [89,113] and this property is also required for
neuronal migration in early brain development [101]. More impor-
tantly, increased motility of C6 cells was only seen when a full length
Cx43 was expressed while cells expressing a carboxy-terminal trun-
cated Cx43 did not show it, implying an important role for the
carboxyl tail of Cx43 in the regulation of glioma cell migration
[76,104]. Similarly, Cx43 truncated at the carboxy-terminal part can-
not rescue the migration defect of neuroblasts in embryonic brain
[100]. In fact, it appears that the carboxyl tail of Cx43 may be sufﬁ-
cient to mediate migration, such as in the case in LN18 human glioma
cells [103]. Furthermore, a recent report has identiﬁed amino acids
257 to 382 in the carboxyl tail region to be enough for promoting mi-
gration of HeLa cells by Cx43, independent on gap junction and hemi-
channel formations [97]. Intriguingly, the carboxyl tail is functional
despite of its cytosolic distribution and accordingly, it has been pro-
posed that it mediates migration by activation of p38 MAPK [97].
Such an observation means that the carboxyl tail of Cx43 may not
only regulate cell proliferation (as described in Section 3.1 of this
review) but also modulates cell migration.
The necessary presence of the carboxyl tail of Cx43 for cell migra-
tion might be due to the fact that it contains protein interaction sites
that could be a part of a “signalosome” complex controlling particular
signaling pathways. Certainly, p38 MAPK could be part of a signalo-
some with Cx43 being a scaffold protein to improve phosphorylation
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mediate actin organization and cell migration induced by growth fac-
tors [114–116].
In addition, the carboxyl tail of Cx43 interacts and associates with
cytoskeletal proteins including F-actin, β-tubulin, N-cadherin and
actin-binding proteins such as drebrin and cortactin [35,98,117,118].
Furthermore, Cx43 is suspected to be involved in cell polarity as
Cx43-null neural crest cells show a loss of polarity which resulted in
reduced migration [91]. In fact, Cx43-null cells also show aberrant
distribution of focal adhesion complex proteins such as vinculin
[91], indicating that Cx43 may have an unexplored role in the leading
edge dynamics of migrating cells. Furthermore, the tubulin-binding
domain is required for Cx43-dependent cell polarity and motility
[92]. It would be of great interest to explore whether co-localization
of Cx43 and actin-binding proteins (α-actinin, drebrin and IQGAP-
1) observed in neural crest cells [91] also occurs in glioma cells and
a similar mechanism may explain the migratory behavior of glioma
cells.
It is perhaps not too surprising that Cx43 may control migration
via gap-junction independent mechanisms since a glioma cell expres-
sing Cx43 is predicted to operate predominantly in an isolated state,
as it is the case if it has to break away from the tumor core. Moreover,
as suggested above, the fact that Cx43 inhibits growth and promotes
migration ﬁts well the “grow or go” theory of the gliomas. It would
partly explain the heterogeneous expression of Cx43 in the glioma
core especially at the malignant glioblastoma stage; some tumor
cells would be expected to migrate (Cx43 expressing cells) and others
to proliferate (non-expressing Cx43 cells). Indeed, a report recently
shows enhanced Cx43 expression only in the tumor cells at the invad-
ing front [105].BA – Induction of apoptosis
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apoptosis as well as in its prevention (B). A: Cx43 exogenous expression has been associat
down of Cx43 impedes apoptosis [143]. Gap junctional intercellular communication (GJIC)
as excess of Ca2+, inositol triphosphate (IP3) or cyclic nucleotide triphosphate (cAMP/cGM
oxidant stimulation (H2O2) and by the uptake of reactive oxygen species [131]. Moreover, h
duced glutathione (GSH) would decrease the intracellular amount of this free radical scaveng
crine pathways. An excessive glutamate release will be associated with neurotoxicity effect
molecules (glucose, survival factors) or allow the uptake of glutamate that would lead to an
extracellular compartment. The participation to paracrine pathways involving ATP or prost
contribute to a spatial buffering of toxic signals such as glutamate, ROS or Ca2+. Finally, the
[135,139].Finally, if Cx43 increases glioma cell migration, except in rare cases
[119], we have to consider that Cx43 is not a prerequisite for such a pro-
cess since cells lacking Cx43 can still migrate [91,120,121]. This may
have something to dowith the tissue context since Cx43 inhibitsmigra-
tion in breast carcinoma cells [122,123] and skin cells [124]. In the brain,
the role of Cx43 in astrocyte migration remains to be clariﬁed. While a
recent report shows that downregulation of Cx43 protein in cultured
astrocytes reduces their motility in vitro [125], a similar study showed
the opposite effect [126]. The evidence for Cx43 required for the migra-
tion of neural progenitors is consistent in two studies [100,101]. It is
therefore safe to conclude that the control of cell migration by Cx43 is
heavily dependent on the inherent migratory state of the cells, which
is expected to be altered in pathological conditions.
3.3. Effect on apoptosis
Resistance to apoptosis is another hallmark of cancer [29,30]. In
this context, the existence of GJIC allowing cell death/survival signals
to pass through one cell to another appears particularly relevant, and
their involvement in cell death is beginning to be a subject of intense
interest [127], both in the CNS and in peripheral tissues [128].
3.3.1. Regulation of apoptosis by channel-dependent mechanisms
It remains controversial whether connexin-mediated GJIC are pro-
or anti-apoptotic. While a substantial amount of data demonstrates a
correlation between GJIC and apoptotic activities [129–134], others
show that GJIC may hinder the occurrence of apoptosis [135–139].
One explanation to this apparent contradiction may be attributed to
regulation of both pro- (Map4k) and anti-apoptotic (Bcl-xL) genes
by Cx43, which were identiﬁed from transcriptome analysis of – Prevention from apoptosis
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of apoptosis raises controversies. Thus, Cx43 may be involved in the induction (A) of the
ed with a decreased activity of the anti-apoptotic molecule bcl-2 [130] and the knock-
may promote the trafﬁcking of molecules involved in the induction of apoptosis such
P) [127,128]. Hemichannels may also participate to apoptosis by their opening under
emichannels may be involved in the release of intracellular molecules. A release of re-
er [141]. Adenosine triphosphate (ATP) and glutamate release may participate to para-
s [150]. B: Nevertheless, hemichannels may also participate to the uptake of beneﬁcial
increased survival [128]. The release of GSH may allow a direct inception of ROS in the
aglandins (PG) may also be linked to increased survival [128,151]. Moreover, GJIC may
exogenous expression of Cx43 has also been related to a decreased activity of caspase 3
2064 W.-C. Sin et al. / Biochimica et Biophysica Acta 1818 (2012) 2058–2067Cx43-null astrocytes [54]. The common point to these contradictory
studies is that GJIC can mediate a large number of signals that may
be deleterious or beneﬁcial (Fig. 2). Among the ‘cell death messen-
gers’ capable of passing through the connexin channels, Ca2+ is per-
haps the most important as it affects several crucial apoptosis
effectors [140]. On the contrary, some of the ‘suspected’ beneﬁcial
molecules that can pass through gap junction channels include me-
tabolites such as glucose and ATP in some conditions or a reducing
agent such as glutathione (GSH) [141,142].
In accordance with the ﬁrst hypothesis that Cx43 promotes apo-
ptosis, it has been shown on organotypic hippocampal slices that
apoptosis following injury was increased in null-mutant Cx43 new-
born mice in comparison with wild-type animals [143]. Moreover,
well-known gap junction inhibitors such as carbenoxolone and/or
18-beta-glycyrrhetinic acid tend to prevent apoptosis [132,144].
Although how Cx43 exerts its apoptotic effect is unclear, at least
one report has correlated increased apoptosis in Cx43-expressing
human glioblastoma cells with reduced activity of the anti-apoptotic
factor bcl-2 [130]. The second hypothesis that proposes GJIC prevents
apoptosis is directly demonstrated by a study in which Cx43 increases
the resistance of C6 glioma cells to apoptosis by inhibiting caspase-3
activation [135]. Other evidence that suggests Cx43 promotes cell
survival is mainly derived from Cx43-mediated neuroprotection in
brain injury models such as in ischemia stroke [137–139]. The knock-
down of Cx43 leads to increased lesion area with greater neuronal
death and a simultaneous increase in caspase-3 activity [137]. It is be-
lieved that astrocytic network connected by Cx43 acts as a sink to
buffer neurotoxic molecules following mechanical or ischemic lesions
[145]. Therefore, Cx43 expression in neoplastic astrocytes may pro-
mote cell survival in a similar fashion.
3.3.2. Regulation of apoptosis by channel-independent mechanisms
There are plenty of conﬂicting evidence regarding GJIC-independent
regulation of apoptosis. An in vitromodel showed that Cx43 expression
is associated with channel-independent reduction of apoptosis in C6
glioma cells [146]. Some studies have proposed the adhesive properties
of Cx43 contribute to the sensitivity of glioblastoma to apoptosis [147].
But for the most part there are more studies demonstrating the hemi-
channel function of Cx43 in affecting apoptosis. Interestingly, several
factors related to apoptosis induction (Ca2+, NO) are also involved in
the opening/closing of the hemichannels in gliomas and astrocytes
[148,149]. It is conceivable that Cx43 hemichannels may inﬂuence apo-
ptosis by allowing the transfer of beneﬁcial (ATP, prostaglandins) or
toxic molecules (glutamate) between the cell and the extracellular
compartment [150–152].
4. Conclusions
The negative growth property of Cx43 places it as tumor suppres-
sor, but overwhelming evidence suggests it has a pivotal role in mi-
gration. It is thus clear that targeting gap junction proteins can both
deter and enhance gliomagenesis, warranting careful exploration of
the mechanisms involved. The enhancement of cell migration by
Cx43 may be consistent with the fact that a migrating cell is usually
not proliferating at the same time. On the other hand, the role of
Cx43 may be cell type-speciﬁc and therefore varies throughout the
development of tumor depending on which kind of cells are the ‘driv-
er’ at that particular stage of gliomagenesis [153]. It will be helpful to
have either a 3D in vitro system or an animal model to decipher the
seemingly opposing role of Cx43 in glioma formation. Either route
presents its own difﬁculties. The complicated microenvironment of
the brain is difﬁcult to replicate in vitro while the search for a perfect
rodent model is still a challenge as the origin and progression of glio-
mas remain to be clariﬁed. Recently, the role of Cx43 in breast tumor-
igenesis has been explored in a Cx43 mutant mouse model in which
reduced Cx43 levels leads to increased mammary gland metastasisto lung [154]. So far, there is no evidence to suggest mice harboring
Cx43-deﬁcient astrocytes are prone to form gliomas, which might
be due to the compensatory increase of other gap junction proteins
in Cx43-deﬁcient astrocytes [155].
Although the therapeutic potential of Cx43 in cancer has been ex-
plored [156], the clinical application is uncertain until the signaling
mediated by Cx43 in glioma growth and invasion is fully resolved.
As a multi-domain protein, the mechanisms by which Cx43 can medi-
ate cellular functions, whether via its channel, hemichannel or cyto-
plasmic tail ultimately determines its role in gliomagenesis. Finally,
in situ analysis with well validated antibodies on primary human
GBM in large scale studies will help to establish whether the apparent
heterogeneous protein expression of Cx43 is correlated to its oppos-
ing roles in gliomagenesis, and also to explore the feasibility of Cx43
as a diagnostic or prognostic biomarker.Acknowledgements
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